Fisher & Paykel Healthcare (FPH) Stock Price, Fundamentals & Analysis
Price
36.31 AUD
+0.55%
Last trade: Sep 25, 2026, 04:10 PM GMT+10
Updated: Sep 27, 2026, 07:44 PM GMT+10
Price history
Over the past year FPH traded between 26.67 AUD and 37.24 AUD, closing at 36.31 AUD on Sep 25, 2026.
Key statistics
| Market cap | 21.32B AUD |
|---|---|
| P/E ratio (TTM) | 56.7 |
| Forward P/E | 41 |
| EPS (TTM) | 0.64 NZD |
| Dividend yield | 1.2% |
| Annual dividend | 0.44 AUD |
| Ex-dividend date | Jun 22, 2026 |
| Payout ratio | 54% |
| 52-week range | 26.51 – 37.71 |
| 52-week change | 13.2% |
| Beta | 0.9 |
| Price / book | 12.44 |
| Revenue (TTM) | 2.31B NZD |
| Revenue growth (YoY) | 14% |
| Gross margin | 63.7% |
| Operating margin | 28.7% |
| Profit margin | 20.3% |
| Return on equity | 23.4% |
| Debt / equity | 6.9 |
| Volume | 572,088 |
| Average volume | 364,845 |
| Next earnings | Nov 24, 2026 |
| Exchange | ASX |
Profile
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Employees
- 7,357
- Headquarters
- Auckland, New Zealand
- Website
- fphcare.com
Fisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia Pacific, and internationally. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital. It also offers adult respiratory products, including airvo system, optiflow nasal high flow therapy, invasive ventilation, and noninvasive ventilation. In addition, the company provides infant respiratory products, such as resuscitation, invasive ventilation, continuous positive airway pressure (CPAP), and nasal high flow products. Further, it offers hospital products comprising humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, software and data management products, and humidifiers. Fisher & Paykel Healthcare Corporation Limited was founded in 1934 and is headquartered in Auckland, New Zealand.
Overview
What FPH does
Fisher & Paykel Healthcare (FPH) designs, manufactures, and sells medical devices for respiratory care and surgery. The company serves hospitals and homecare patients across North America, Europe, and the Asia Pacific, with products ranging from ventilators and humidifiers to masks and CPAP devices for conditions such as obstructive sleep apnea. Founded in 1934 and headquartered in Auckland, New Zealand, FPH employs 7,357 people. It is listed on the ASX and is part of the ASX 200, sitting alongside peers such as ResMed (RMD) and Cochlear (COH).
Key numbers explained
- 36.31 AUD is the current share price; the +0.55% move shows today's percentage change.
- The trailing P/E ratio of 56.7 divides the share price by the last 12 months' earnings per share (0.64 NZD), indicating how much investors pay for each dollar of recent earnings.
- The forward P/E ratio of 41 uses expected future earnings, which can be lower if growth is anticipated.
- Dividend yield of 1.2% tells you the annual dividend as a percentage of the share price; the ex-dividend date is 22 Jun 2026.
- 54% of earnings are paid out as dividends, meaning the company retains the rest for reinvestment.
- Beta of 0.9 suggests the share tends to move about 10% less than the overall market.
- The 52-week range of 26.51 – 37.71 shows the lowest and highest traded prices over the past year, with a 13.2% gain from a year ago.
- Return on equity of 23.4% measures how efficiently the company generates profit from shareholders' funds.
What to watch
- Revenue growth of 14% year over year and a profit margin of 20.3% show top-line expansion and cost control.
- The operating margin of 28.7% indicates how much of each revenue dollar remains after operating expenses.
- A low debt-to-equity ratio of 6.9% points to a conservative capital structure.
- The price-to-book of 12.44 compares the share price to the company's book value, which can be high for asset-light or high-growth businesses.
- The next earnings release is scheduled for 24 Nov 2026, a common catalyst for price movement.
- Investors often compare FPH with other medical device names such as Pro Medicus (PME), Sonic Healthcare (SHL), and Ryman Healthcare (RYM) to gauge sector trends.
Latest news & filings
No recent headlines.
Frequently asked questions
Does FPH pay a dividend?
Yes, Fisher & Paykel Healthcare pays a dividend with a yield of 1.2%; the next ex-dividend date is 22 Jun 2026.
What is the FPH P/E ratio?
The trailing P/E ratio is 56.7, while the forward P/E ratio on expected earnings is 41.
Where can I buy FPH?
FPH trades on the ASX under the symbol FPH; you can buy it through any broker that provides access to the Australian market.
How much does FPH pay in dividends?
The company pays out 54% of its earnings as dividends, with a dividend yield of 1.2%.
What sector is Fisher & Paykel Healthcare in?
It operates in the Healthcare sector, specifically in Medical Instruments & Supplies.
How has FPH performed over the past year?
The share price has risen 13.2% over the last 52 weeks, trading within a range of 26.51 – 37.71.
Related
More on FPH
Track FPH in your portfolio
Hold FPH at XTB, IBKR, Tradeville, Revolut or Trading 212? InvestPane brings every broker into one dashboard — allocation, performance and dividends in one place.
Start free